Osiris Therapeutics (OSIR) stock price, revenue, and financials

Osiris Therapeutics market cap is $655.7 m, and annual revenue was $142.82 m in FY 2018

$655.7 M

OSIR Mkt cap, 16-Apr-2019

$142.8 M

Osiris Therapeutics Revenue FY, 2018
Osiris Therapeutics Gross profit (FY, 2018)104.7 M
Osiris Therapeutics Gross profit margin (FY, 2018), %73.3%
Osiris Therapeutics Net income (FY, 2018)36.9 M
Osiris Therapeutics Cash, 31-Dec-201816.4 M

Osiris Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2018

Revenue

142.8m

Cost of goods sold

38.1m

Gross profit

104.7m

Gross profit Margin, %

73%

Sales and marketing expense

36.4m67.5m

R&D expense

5.0m3.4m6.8m

General and administrative expense

15.3m7.6m19.6m

Operating expense total

20.5m47.9m94.8m

EBIT

(2.8m)1.7m

Pre tax profit

10.5m

Income tax expense

1.3m(97.0k)26.0m

Net Income

41.6m(10.0m)36.9m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2018Q2, 2018Q3, 2018

Revenue

31.6m33.9m36.5m

Cost of goods sold

8.9m9.7m9.8m

Gross profit

22.8m24.2m26.7m

Gross profit Margin, %

72%71%73%

Sales and marketing expense

16.3m16.9m15.9m

R&D expense

885.0k670.0k1.1m1.2m2.3m2.3m1.5m1.7m1.6m

General and administrative expense

4.0m7.2m9.3m10.9m14.5m17.3m7.4m3.4m4.3m

Operating expense total

4.9m8.5m10.4m12.2m16.8m19.6m25.3m22.0m22.7m

EBIT

(615.0k)(66.0k)1.2m(2.5m)2.2m

EBIT margin, %

(8%)6%

Pre tax profit

(2.3m)2.5m3.9m

Income tax expense

130.0k(130.0k)(104.0k)(367.0k)132.0k(36.0k)(34.0k)(100.0k)

Net Income

(1.7m)(1.4m)(1.9m)645.0k1.2m(658.0k)(2.3m)2.5m4.2m

Osiris Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2017FY, 2018

Cash

2.4m2.2m3.1m16.4m

Accounts Receivable

15.3m10.0m26.1m22.5m

Inventories

1.9m9.8m11.3m9.6m

Current Assets

84.1m86.3m72.9m70.2m

PP&E

1.9m2.1m3.6m2.9m

Total Assets

92.1m88.5m78.1m101.5m

Accounts Payable

4.8m7.5m5.3m4.1m

Short-term debt

Current Liabilities

10.8m9.2m35.1m20.6m

Long-term debt

Total Debt

Total Liabilities

11.1m12.8m36.7m23.0m

Additional Paid-in Capital

282.7m287.3m283.9m284.2m

Retained Earnings

(201.8m)(211.6m)(242.3m)(205.4m)

Total Equity

80.9m75.7m41.4m78.5m

Financial Leverage

1.1 x1.2 x1.9 x1.3 x

Osiris Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2017FY, 2018

Net Income

8.8m36.9m

Depreciation and Amortization

587.0k940.0k688.0k873.0k

Accounts Receivable

(4.7m)(7.5m)(2.8m)

Inventories

(651.0k)(7.9m)

Accounts Payable

(2.8m)(57.0k)

Cash From Operating Activities

(13.3m)(3.2m)(5.2m)7.3m

Purchases of PP&E

(528.0k)(1.1m)(242.0k)

Cash From Investing Activities

11.6m1.1m5.3m6.0m

Cash From Financing Activities

2.2m1.9m128.0k7.0k

Income Taxes Paid

539.0k619.0k134.0k(318.0k)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2018Q2, 2018Q3, 2018

Net Income

(2.3m)164.0k4.4m

Depreciation and Amortization

211.0k426.0k658.0k

Accounts Receivable

6.8m15.1m256.0k474.0k7.6m720.0k562.0k

Inventories

1.7m2.3m5.5m8.8m11.9m13.3m15.8m

Accounts Payable

4.0m8.0m9.3m9.8m9.2m9.6m

Cash From Operating Activities

337.0k4.9m13.0m

Purchases of PP&E

(100.0k)(134.0k)(187.0k)

Cash From Investing Activities

(55.0k)15.1m15.6m

Osiris Therapeutics Ratios

USDY, 2018

Revenue/Employee

420.7k

Financial Leverage

1.3 x

Osiris Therapeutics Employee Rating

2.431 votes
Culture & Values
2.2
Work/Life Balance
2.0
Senior Management
2.0
Salary & Benefits
2.9
Career Opportunities
2.6
Source